Olanzapine in treatment-refractory schizophrenia: Results of an open- label study

Journal of Clinical Psychiatry

Volumn 58, Issue 11, 1997, Pages 479-483

  Martín, Joaquín ^a   Gómez, Juan Carlos ^b   García Bernardo, Enrique ^c   Cuesta, Manuel ^d   Alvarez, Enrique ^e   Gurpegui, Manuel ^f   Mateo, Ildefonso ^a   Moríñigo, Angel ^a   Noval, Dolores ^a   Soler, Rosa ^a   Palomo, Tomás ^c   Peralta, Victor ^d   Pérez Blanco, Fina ^e   Massip, Carlos ^e  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b ELI LILLY AND COMPANY   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Instituto de Investigación Sanitaria de Navarra   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; AGITATION; ANXIETY; ARTICLE; CLINICAL ARTICLE; COUGHING; DELUSION; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEVER; HALLUCINATION; HOSTILITY; HUMAN; HYPERKINESIA; INSOMNIA; MALE; ORAL DRUG ADMINISTRATION; PERSONALITY DISORDER; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 1842404208     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n1103     Document Type: Article

References (25)

1. Brenner HD, Dencker SJ, Goldstein MJ, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16:551-561
2. Turkelsen KG, Grosser RC. Estimating clozapine's cost to the nation. Hospital and Community Psychiatry 1990;41:863-869
3. Christisen GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991;17:217-245
4. Martín J, Moríñigo A, Mateo I, et al. La carbamazepina: un tratamiento adjunto eficaz en las esquizofrenias. Actas Luso Esp Neurol Psiquitr Cienc Afines 1989;17:245-250
5. Moríñigo A, Martín J, González S, et al. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside Journal of Clinical Psychiatry 1990;11:199-207
6. Johns CA, Thompson JW. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophr Bull 1995;21: 607-619
7. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
8. Marder SR, Van Putten T. Who should receive clozapine? Arch Gen Psychiatry 1988;45:865-868
9. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. N Engl J Med 1993;329:162-167
10. Wyatt RJ. Neuioleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-351
11. Umbricht D, Kane JM. Risperidone: efficacy and safety. Schizophr Bull 1995;21:593-606
12. Cardoni AA. Risperidone: review and assessment of its role in the treatment of schizophrenia. Ann Pharmacother 1995;29:610-618
13. Smith RC, Chua JW, Lipetsker B, et al. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry 1996;57:460-466
14. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96
15. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind fixed dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167
16. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-124
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
18. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
19. Peralta V, Cuesta MJ. Validación de la escala de los síndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles. Actas Luso Esp Neurol Psiquitr Cienc Afines 1994;21:44-50
20. Peralta V, Cuesta MJ. Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. Psychiatry Res 1994;53: 31-40
21. Guy W. ECDEU Assessment for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
22. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Early Clinical Drug Evaluation Unit Intercom 1975;4:3-6
23. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(suppl 212):11-19
24. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
25. US Food and Drug Administration. Coding Symbols for Thesaurus of Adverse Drug Reaction Terms (COSTART). National Adverse Drug Reaction Dictionary. Rockville, Md: US Government Printing Office; 1989